Abstract 3312: Oncolytic HSV (34.5ENVE) sensitizes bortezomib-induced cancer cell killing through induction of RIP1 dependent necroptosis.
Brian Hurwitz(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Balveen Kaur(Augusta University), Ji Young Yoo(The University of Texas MD Anderson Cancer Center), Matthew Old, Jeffery Wojton(The Ohio State University Wexner Medical Center), Chelsea Bolyard(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jun-Ge Yu(The Ohio State University Wexner Medical Center)
Cited by 0
Related Papers
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
|Proceedings of the National Academy of Sciences|2006|360
Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth
|Cancer Cell|2015|336
Inhibition of SOAT1 Suppresses Glioblastoma Growth via Blocking SREBP-1–Mediated Lipogenesis
|Clinical Cancer Research|2016|332
VEGF-specific Short Hairpin RNA–expressing Oncolytic Adenovirus Elicits Potent Inhibition of Angiogenesis and Tumor Growth
|Molecular Therapy|2007|150
RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21
|Molecular Therapy|2017|147